XML 51 R43.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Schedule of Reconciliation of U.S Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate

A reconciliation of the U.S. federal statutory income tax rate to the Company’s effective income tax rate is as follows:

 

    Year Ended December 31,  
    2023     2022  
Federal statutory income tax rate     (21.0 )%     (21.0 )%
Research and development tax credits     (4.3 )     (3.1 )
State taxes, net of federal benefit     (7.8 )     (4.3 )
Stock-based compensation     1.4       0.6  
Uncertain tax position reserves     0.8       4.6  
Other     (0.3 )     0.3  
Change in deferred tax asset valuation allowance     31.2       22.9  
Effective income tax rate     %
    %
Schedule of Net Deferred Tax Assets

Net deferred tax assets as of December 31, 2023 and 2022 consisted of the following:

 

    December 31,  
    2023     2022  
Deferred tax assets:            
Net operating loss carryforwards   $ 142,506     $ 132,560  
Research and development tax credit carryforwards     52,843       48,854  
Section 174 capitalized research and development expenses     55,572       38,894  
Stock-based compensation expense     25,898       20,048  
Lease liability     29,855       29,717  
Deferred revenue     27,452       29,922  
Accrued expenses     3,540       4,044  
Section 163(j) limitation     3,741       2,303  
Depreciation and amortization     398       396  
Other     169       200  
Total deferred tax assets   $ 341,974     $ 306,938  
Deferred tax liabilities:                
Depreciation and amortization            
Right of use assets     (29,165 )     (29,568 )
Total deferred tax liabilities     (29,165 )     (29,568 )
Valuation allowance   $ (312,809 )   $ (277,370 )
Net deferred tax assets   $     $  
Summary of Changes In Valuation Allowance for Deferred Tax Assets Changes in the valuation allowance for deferred tax assets during the years ended December 31, 2023 and 2022 related primarily to the increases in NOLs, research and development tax credit carryforwards and capitalized research and development expenses pursuant to IRC Section 174, and stock-based compensation were as follows:

 

    Year Ended December 31,  
    2023     2022  
Valuation allowance at beginning of year   $ (277,370 )   $ (220,114 )
Decreases recorded as benefit to income tax provision            
Increases recorded to income tax provision     (35,439 )     (57,256 )
Valuation allowance as of end of year   $ (312,809 )   $ (277,370 )
Schedule of Change In Unrecognized Tax Benefits Roll Forward The changes in the Company’s unrecognized tax benefits for the years ended December 31, 2023 and 2022 were as follows:

 

    Year Ended December 31,  
      2023       2022  
Balance at beginning of year   $ 12,528     $  
Increase in unrecognized tax benefits as a result of tax positions taken during the year     1,001       12,528  
Reduction to unrecognized tax benefits            
Balance at end of year   $ 13,529     $ 12,528